SRC and cancer: The sphere formation assay and ALDEFLUOR assay further confirmed that the cancer stemness markers, number and size of spheres, and ALDH activity were significantly reduced in troxerutin-treated cells, consolidating their targeting of the CD155/SRC/β-catenin axis to inhibit OS stemness (Fig. 8N–U).